Phageolytix is an innovative company focused on leveraging bacteriophage technology to combat the escalating challenge of multi-drug resistant pathogenic and industrial bacteria in the environment and agriculture sectors.
At Phageolytix, our unique technological approach is set to revolutionize the field of bacteriophage therapy. We have developed a proprietary process to isolate, identify, and purify bacteriophages that can effectively target specific bacterial strains.
Phage therapy presents a promising adjunct or alternative to traditional antimicrobial strategies in the management of human disease, particularly in cases complicated by multidrug-resistant pathogens. In chronic respiratory disorders such as bronchiectasis, recurrent infections with organisms like Pseudomonas aeruginosa and Haemophilus influenzae contribute significantly to disease progression, airway inflammation, and reduced quality of life. Phage therapy offers a pathogen-specific approach capable of disrupting these persistent infections while preserving the native microbiota. Its potential for biofilm penetration and synergy with antibiotics further enhances its therapeutic value in bronchiectasis. More broadly, phage therapy may serve as a critical tool in mitigating the clinical impact of antimicrobial resistance across a range of infectious diseases.